Literature DB >> 18346810

Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus.

Claudete M Zanatta1, Fernando Gerchman, Lucas Burttet, Gustavo Nabinger, Maria C Jacques-Silva, Luís H Canani, Jorge L Gross.   

Abstract

AIM: To evaluate the relationship of plasma endothelin-1 (ET-1) levels, a marker of endothelial dysfunction, and urinary albumin excretion in patients with type 2 diabetes mellitus (DM).
METHODS: Cross-sectional study was conducted in 279 patients (132 males, mean age: 58.7+/-11.0 years, mean DM duration: 11.3+/-8.1 years). Urinary albumin excretion, ET-1, and insulin were measured. Insulin sensitivity was estimated by homeostasis model assessment (HOMA-ir) index.
RESULTS: ET-1 was associated with urinary albumin excretion after controlling for age, gender, body mass index, blood pressure, HbA1c test, and total cholesterol (R=0.436; adjusted R(2)=0.190, P<0.01). Furthermore, there was a progressive increase in plasma ET-1 levels from patients with normoalbuminuria (n=187, 0.92+/-0.50pg/ml), microalbuminuria (n=68, 1.13+/-0.52pg/ml) to macroalbuminuria (n=24, 1.93+/-1.10pg/ml, P<0.01).
CONCLUSION: There is an independent association of plasma ET-1 levels with urinary albumin excretion. In addition, plasma ET-1 levels started to increase in the normal values of urinary albumin excretion suggesting that in patients with type 2 DM endothelial dysfunction is already present, in urinary albumin excretion values considered normal.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18346810     DOI: 10.1016/j.diabres.2007.12.024

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  20 in total

Review 1.  Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.

Authors:  Emaad M Abdel-Rahman; Lawand Saadulla; W Brian Reeves; Alaa S Awad
Journal:  J Gen Intern Med       Date:  2011-10-18       Impact factor: 5.128

2.  Endothelin-1 response to glucose and insulin among African Americans.

Authors:  Stephanie DeLoach; Yonghong Huan; Constantine Daskalakis; Bonita Falkner
Journal:  J Am Soc Hypertens       Date:  2010-08-21

Review 3.  Molecular insights and therapeutic targets for diabetic endothelial dysfunction.

Authors:  Jian Xu; Ming-Hui Zou
Journal:  Circulation       Date:  2009-09-29       Impact factor: 29.690

4.  Argirein alleviates diabetic nephropathy through attenuating NADPH oxidase, Cx43, and PERK in renal tissue.

Authors:  C Hu; X D Cong; De-Zai Dai; Y Zhang; G L Zhang; Y Dai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-01-26       Impact factor: 3.000

5.  Evaluation of Circulating Plasma VEGF-A, ET-1 and Magnesium Levels as the Predictive Markers for Proliferative Diabetic Retinopathy.

Authors:  Gopal Niranjan; A R Srinivasan; K Srikanth; Gowda Pruthu; R Reeta; Ramasamy Ramesh; Rajendiran Anitha; V Mohana Valli
Journal:  Indian J Clin Biochem       Date:  2018-05-03

Review 6.  Endothelin Receptor Antagonists: New Hope for Renal Protection?

Authors:  Sheldon Tobe; Donald E Kohan; Ranjit Singarayer
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

Review 7.  Endothelin antagonists for diabetic and non-diabetic chronic kidney disease.

Authors:  Donald E Kohan; David M Pollock
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

Review 8.  Endothelin, hypertension and chronic kidney disease: new insights.

Authors:  Donald E Kohan
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-03       Impact factor: 2.894

Review 9.  Renal endothelial dysfunction in diabetic nephropathy.

Authors:  Huifang Cheng; Raymond C Harris
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2014

10.  Diabetic nephropathy.

Authors:  Themis Zelmanovitz; Fernando Gerchman; Amely Ps Balthazar; Fúlvio Cs Thomazelli; Jorge D Matos; Luís H Canani
Journal:  Diabetol Metab Syndr       Date:  2009-09-21       Impact factor: 3.320

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.